Core Xarelto Patent Expiration
The primary composition-of-matter patent for Xarelto (rivaroxaban), US Patent 7,157,456, expires on September 30, 2024.[1][2] This covers the drug's active ingredient and is the key barrier to generic entry in the US.
When Can Generics Enter the Market?
Generic versions of Xarelto face delays beyond the '456 patent due to pediatric exclusivity extensions, pushing the effective market entry to January 2028 for most ANDA filers, assuming no further litigation wins for Bayer/Janssen.[1][3] Some generics could launch earlier via settlements, like those with Mylan (Viatris) in mid-2024 at-risk, though courts have upheld Bayer's patents in recent disputes.[2]
Why Multiple Patents and Extensions?
Xarelto is protected by over 150 patents listed in the FDA Orange Book, including method-of-use patents (e.g., US 7,592,339 expiring 2024) and formulation patents extending to 2033.[1][2] Pediatric exclusivity adds 6 months to several, but the main cluster ends 2024-2028. Bayer has defended these aggressively, with the latest loss in 2023 allowing at-risk launches.[3]
Status of Ongoing Litigation
Federal Circuit rulings in 2023 invalidated some secondary patents, enabling earlier generic challenges, but Bayer won on others like stereoisomer claims.[2][4] Check DrugPatentWatch.com for live updates on ANDA Paragraph IV suits.[1]
International Expiration Dates
- Europe: Core patent EP1284963 expires December 31, 2023; generics launched January 2024.[5]
- Japan: Expires 2028.[5]
- Canada: Main patent expired 2023.[5]
Impact on Pricing and Availability
Post-2024 patent cliffs, US list prices for 20mg Xarelto (30 tablets) exceed $500, but generics could drop it 80-90% by 2028, similar to Eliquis trends.[3][6] Patients on Xarelto for DVT/PE/stroke prevention should discuss switches with doctors as options expand.
Sources
[1]: DrugPatentWatch.com - Xarelto Patents
[2]: FDA Orange Book - Rivaroxaban
[3]: PhRMA Patent Settlement Tracker
[4]: Federal Circuit - Bayer v. MSN (2023)
[5]: EMA Patent Register
[6]: IQVIA Market Data